Novogen Ltd. (NASDAQ:NVGN) has been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokers have set a 12-month consensus price target of $5.00 for the company, according to Zacks. Zacks has also given Novogen an industry rank of 99 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright restated a “buy” rating on shares of Novogen in a report on Tuesday, September 27th.
Shares of Novogen (NASDAQ:NVGN) traded down 1.2459% on Wednesday, reaching $1.8072. The company’s stock had a trading volume of 3,998 shares. The firm has a 50 day moving average of $1.94 and a 200 day moving average of $2.03. Novogen has a 52-week low of $1.72 and a 52-week high of $3.09. The company’s market cap is $31.06 million.
Novogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company’s operations include CanTx Inc, its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novogen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.